Autoantibody cancer biomarker: Extracellular protein kinase A

Maria V. Nesterova, Natalie Johnson, Christopher Cheadle, Susan E. Bates, Sridhar Mani, Constantine A. Stratakis, Islam Kahn, Rishab K. Gupta, Yoon S. Cho-Chung

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

In cancer cells, cyclic AMP-dependent protein kinase (PKA) is secreted into the conditioned medium. This PKA, designated as extracellular protein kinase A (ECPKA), is markedly upregulated in the sera of patients with cancer. The currently available tumor markers are based on the antigen determination method and lack specificity and sensitivity. Here, we present an ECPKA autoantibody detection method for a universal biomarker that detects cancer of various cell types. We tested sera from 295 patients with cancers of various cell types, 155 normal controls, and 55 patients without cancer. The specificity and sensitivity of this autoantibody enzyme immunoassay method were compared with the conventional antigen determination method by receiver-operating characteristic plots. In the sera, the presence of autoantibody directed against ECPKA was highly correlated with cancer. High anti-ECPKA autoantibody titers (frequency, 90%; mean titer, 3.0) were found in the sera of patients with various cancers, whereas low or negative titers (frequency, 12%; mean titer, 1.0) were found in the control group. The receiver-operating characteristic plot showed that autoantibody enzyme immunoassay exhibited 90% sensitivity and 88% specificity, whereas the enzymatic assay exhibited 83% sensitivity and 80% specificity. These results show that the autoantibody method distinguished between patients with cancer and controls better than the antigen method could. Our results show that autoantibody ECPKA is a universal serum biomarker for cancers of various cell types.

Original languageEnglish (US)
Pages (from-to)8971-8974
Number of pages4
JournalCancer Research
Volume66
Issue number18
DOIs
StatePublished - Sep 15 2006

Fingerprint

Tumor Biomarkers
Cyclic AMP-Dependent Protein Kinases
Autoantibodies
Neoplasms
Sensitivity and Specificity
Serum
Immunoenzyme Techniques
Antigens
ROC Curve
Enzyme Assays
Conditioned Culture Medium
Protein Kinases
Control Groups

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Nesterova, M. V., Johnson, N., Cheadle, C., Bates, S. E., Mani, S., Stratakis, C. A., ... Cho-Chung, Y. S. (2006). Autoantibody cancer biomarker: Extracellular protein kinase A. Cancer Research, 66(18), 8971-8974. https://doi.org/10.1158/0008-5472.CAN-06-1049

Autoantibody cancer biomarker : Extracellular protein kinase A. / Nesterova, Maria V.; Johnson, Natalie; Cheadle, Christopher; Bates, Susan E.; Mani, Sridhar; Stratakis, Constantine A.; Kahn, Islam; Gupta, Rishab K.; Cho-Chung, Yoon S.

In: Cancer Research, Vol. 66, No. 18, 15.09.2006, p. 8971-8974.

Research output: Contribution to journalArticle

Nesterova, MV, Johnson, N, Cheadle, C, Bates, SE, Mani, S, Stratakis, CA, Kahn, I, Gupta, RK & Cho-Chung, YS 2006, 'Autoantibody cancer biomarker: Extracellular protein kinase A', Cancer Research, vol. 66, no. 18, pp. 8971-8974. https://doi.org/10.1158/0008-5472.CAN-06-1049
Nesterova MV, Johnson N, Cheadle C, Bates SE, Mani S, Stratakis CA et al. Autoantibody cancer biomarker: Extracellular protein kinase A. Cancer Research. 2006 Sep 15;66(18):8971-8974. https://doi.org/10.1158/0008-5472.CAN-06-1049
Nesterova, Maria V. ; Johnson, Natalie ; Cheadle, Christopher ; Bates, Susan E. ; Mani, Sridhar ; Stratakis, Constantine A. ; Kahn, Islam ; Gupta, Rishab K. ; Cho-Chung, Yoon S. / Autoantibody cancer biomarker : Extracellular protein kinase A. In: Cancer Research. 2006 ; Vol. 66, No. 18. pp. 8971-8974.
@article{120f9ea4c1ff4b72882afbb386b411e3,
title = "Autoantibody cancer biomarker: Extracellular protein kinase A",
abstract = "In cancer cells, cyclic AMP-dependent protein kinase (PKA) is secreted into the conditioned medium. This PKA, designated as extracellular protein kinase A (ECPKA), is markedly upregulated in the sera of patients with cancer. The currently available tumor markers are based on the antigen determination method and lack specificity and sensitivity. Here, we present an ECPKA autoantibody detection method for a universal biomarker that detects cancer of various cell types. We tested sera from 295 patients with cancers of various cell types, 155 normal controls, and 55 patients without cancer. The specificity and sensitivity of this autoantibody enzyme immunoassay method were compared with the conventional antigen determination method by receiver-operating characteristic plots. In the sera, the presence of autoantibody directed against ECPKA was highly correlated with cancer. High anti-ECPKA autoantibody titers (frequency, 90{\%}; mean titer, 3.0) were found in the sera of patients with various cancers, whereas low or negative titers (frequency, 12{\%}; mean titer, 1.0) were found in the control group. The receiver-operating characteristic plot showed that autoantibody enzyme immunoassay exhibited 90{\%} sensitivity and 88{\%} specificity, whereas the enzymatic assay exhibited 83{\%} sensitivity and 80{\%} specificity. These results show that the autoantibody method distinguished between patients with cancer and controls better than the antigen method could. Our results show that autoantibody ECPKA is a universal serum biomarker for cancers of various cell types.",
author = "Nesterova, {Maria V.} and Natalie Johnson and Christopher Cheadle and Bates, {Susan E.} and Sridhar Mani and Stratakis, {Constantine A.} and Islam Kahn and Gupta, {Rishab K.} and Cho-Chung, {Yoon S.}",
year = "2006",
month = "9",
day = "15",
doi = "10.1158/0008-5472.CAN-06-1049",
language = "English (US)",
volume = "66",
pages = "8971--8974",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "18",

}

TY - JOUR

T1 - Autoantibody cancer biomarker

T2 - Extracellular protein kinase A

AU - Nesterova, Maria V.

AU - Johnson, Natalie

AU - Cheadle, Christopher

AU - Bates, Susan E.

AU - Mani, Sridhar

AU - Stratakis, Constantine A.

AU - Kahn, Islam

AU - Gupta, Rishab K.

AU - Cho-Chung, Yoon S.

PY - 2006/9/15

Y1 - 2006/9/15

N2 - In cancer cells, cyclic AMP-dependent protein kinase (PKA) is secreted into the conditioned medium. This PKA, designated as extracellular protein kinase A (ECPKA), is markedly upregulated in the sera of patients with cancer. The currently available tumor markers are based on the antigen determination method and lack specificity and sensitivity. Here, we present an ECPKA autoantibody detection method for a universal biomarker that detects cancer of various cell types. We tested sera from 295 patients with cancers of various cell types, 155 normal controls, and 55 patients without cancer. The specificity and sensitivity of this autoantibody enzyme immunoassay method were compared with the conventional antigen determination method by receiver-operating characteristic plots. In the sera, the presence of autoantibody directed against ECPKA was highly correlated with cancer. High anti-ECPKA autoantibody titers (frequency, 90%; mean titer, 3.0) were found in the sera of patients with various cancers, whereas low or negative titers (frequency, 12%; mean titer, 1.0) were found in the control group. The receiver-operating characteristic plot showed that autoantibody enzyme immunoassay exhibited 90% sensitivity and 88% specificity, whereas the enzymatic assay exhibited 83% sensitivity and 80% specificity. These results show that the autoantibody method distinguished between patients with cancer and controls better than the antigen method could. Our results show that autoantibody ECPKA is a universal serum biomarker for cancers of various cell types.

AB - In cancer cells, cyclic AMP-dependent protein kinase (PKA) is secreted into the conditioned medium. This PKA, designated as extracellular protein kinase A (ECPKA), is markedly upregulated in the sera of patients with cancer. The currently available tumor markers are based on the antigen determination method and lack specificity and sensitivity. Here, we present an ECPKA autoantibody detection method for a universal biomarker that detects cancer of various cell types. We tested sera from 295 patients with cancers of various cell types, 155 normal controls, and 55 patients without cancer. The specificity and sensitivity of this autoantibody enzyme immunoassay method were compared with the conventional antigen determination method by receiver-operating characteristic plots. In the sera, the presence of autoantibody directed against ECPKA was highly correlated with cancer. High anti-ECPKA autoantibody titers (frequency, 90%; mean titer, 3.0) were found in the sera of patients with various cancers, whereas low or negative titers (frequency, 12%; mean titer, 1.0) were found in the control group. The receiver-operating characteristic plot showed that autoantibody enzyme immunoassay exhibited 90% sensitivity and 88% specificity, whereas the enzymatic assay exhibited 83% sensitivity and 80% specificity. These results show that the autoantibody method distinguished between patients with cancer and controls better than the antigen method could. Our results show that autoantibody ECPKA is a universal serum biomarker for cancers of various cell types.

UR - http://www.scopus.com/inward/record.url?scp=33749502582&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749502582&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-06-1049

DO - 10.1158/0008-5472.CAN-06-1049

M3 - Article

C2 - 16982736

AN - SCOPUS:33749502582

VL - 66

SP - 8971

EP - 8974

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 18

ER -